Australia Markets closed

Geron Corporation (GERN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.3300+0.0100 (+0.76%)
At close: 04:00PM EDT
1.3500 +0.02 (+1.50%)
After hours: 07:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.3200
Open1.3600
Bid1.3000 x 3000
Ask1.3900 x 3100
Day's range1.2300 - 1.3800
52-week range0.9900 - 2.2300
Volume2,889,647
Avg. volume2,520,508
Market cap428.192M
Beta (5Y monthly)1.08
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    FOSTER CITY, Calif., May 19, 2022--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 327,400 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

  • Business Wire

    Geron to Present at the H.C. Wainwright Global Investment Conference

    FOSTER CITY, Calif., May 17, 2022--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to present a company overview at the H.C. Wainwright Global Investment Conference. The presentation will be available as an on-demand session beginning May 24, 2022 at 7 a.m. ET.

  • Business Wire

    Geron Corporation Reports First Quarter 2022 Financial Results

    FOSTER CITY, Calif., May 09, 2022--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the first quarter of 2022, including current and projected financial resources.